Press Release

Mount Sinai Receives $4 Million NIH Grant to Address Risk of Acute Kidney Injury After Surgery

Five-year award will use data from more than 320,000 patients at 15 hospitals to develop personalized risk prediction and prevention strategies

New York, NY
(October 27, 2026)

Researchers at the Icahn School of Medicine at Mount Sinai have received a five-year National Institutes of Health grant of approximately $4 million to improve prediction and prevention of postoperative acute kidney injury (AKI), a potentially serious complication after surgery.

Approximately 50 million major noncardiac surgeries are performed annually in the United States, and an estimated 12 percent of them are complicated by postoperative acute kidney injury.

Postoperative acute kidney injury can lengthen hospital stays and, as previous Mount Sinai-led research has shown, increase the risk of chronic kidney disease and death. Because there is currently no direct treatment for the condition, predicting risk and preventing kidney injury are especially important.

During and after surgery, the body undergoes significant stress, and patients may experience fluctuations in blood pressure, heart rate, and breathing, as well as bleeding, say the investigators. The kidneys are particularly sensitive to these changes, making them among the first organs to show signs of injury—what’s known as AKI. The risk is higher in patients with pre-existing kidney or heart conditions, those undergoing major surgery, or those experiencing other complications.

“Postoperative acute kidney injury is a common and serious complication after surgery, yet we still lack reliable ways to identify which patients are most likely to develop it and determine how best to prevent it,” says Andrew Leibowitz, MD, Chair of the Department of Anesthesiology, Perioperative and Pain Medicine, Icahn School of Medicine at Mount Sinai. “This research brings together data from multiple hospitals to develop a more precise approach to predicting risk and, ultimately, to help clinicians tailor preventive strategies to the individual patient.”

The Mount Sinai-led team will analyze data from more than 320,000 patients at 15 hospitals across three health systems to develop and test an artificial intelligence (AI) model that predicts which patients may develop acute kidney injury after surgery. Researchers will also examine whether different patient groups may benefit from different prevention strategies, with the long-term goal of tailoring prevention to each patient.

“Today, we have limited ability to predict who will develop kidney injury after surgery, and prevention strategies are often applied broadly rather than tailored to individuals,” says Ira Hofer, MD, Associate Professor of Anesthesiology, Perioperative and Pain Medicine at the Icahn School of Medicine at Mount Sinai and the lead investigator for the study. “Our goal is to use the wealth of information available in electronic health records to identify patients at risk before surgery and move toward prevention strategies that are better matched to each patient.”

Researchers from Mount Sinai, Vanderbilt University, and the University of California, Los Angeles, will contribute expertise in anesthesiology, nephrology, biomedical informatics, and health data science. The team will use federated learning, a method that allows hospitals to develop a shared AI prediction model without transferring individual patient records between institutions. Each hospital retains its own patient data.

Many existing postoperative acute kidney injury prediction models were developed with relatively small patient populations at individual hospitals. According to the researchers, that can make it difficult to determine whether a model will work reliably at other hospitals or for different patient populations.

“Federated learning gives us a way to learn from a much larger and more diverse patient population while keeping patient-level data within the health systems where it originated,” says Girish N. Nadkarni, MD, MPH, Chair of the Windreich Department of Artificial Intelligence and Human Health, Icahn School of Medicine at Mount Sinai, and Director of the Hasso Plattner Institute for Digital Health at Mount Sinai. “That allows us to ask whether a prediction model can work reliably across different hospitals and patient populations, rather than building a tool around the experience of a single institution.”

The study has two aims. First, researchers will develop and test models to predict whether a patient may develop postoperative acute kidney injury and how severe it may be. Second, they will identify patient groups that might benefit from different prevention strategies.

Researchers will compare the federated learning models with existing prediction approaches and with a model built using pooled data from participating institutions. They will also assess performance across different patient populations, including groups that may be underrepresented in existing models.

The findings are intended to inform future clinical trials that will test whether personalized prevention strategies can reduce postoperative acute kidney injury in patients undergoing surgery.

“Our ultimate goal is to move beyond a one-size-fits-all approach to preventing kidney injury after surgery,” says Dr. Hofer. “By combining expertise across institutions and using data in a way that protects patient privacy, we hope to develop tools that can help clinicians identify risk earlier and choose prevention strategies that are more personalized.”

The research builds on the team’s prior work developing perioperative risk models and applying federated learning across hospitals, including research using the approach to predict COVID-19 mortality. The investigators also have experience using data to identify personalized treatment strategies for sepsis-associated kidney injury.

“If successful, the work could provide a model for using collaborative, privacy-conscious data science to improve prevention of complications beyond kidney injury, particularly in patients undergoing surgery,” says Dr. Nadkarni.

The work is supported by the National Institutes of Health, award number 1R01DK144051-01A1.

About the Icahn School of Medicine at Mount Sinai

The Icahn School of Medicine at Mount Sinai is internationally renowned for its outstanding research, educational, and clinical care programs. It is the sole academic partner for the seven member hospitals* of the Mount Sinai Health System, one of the largest academic health systems in the United States, providing care to New York City’s large and diverse patient population.

The Icahn School of Medicine at Mount Sinai offers highly competitive MD, PhD, MD-PhD, and master’s degree programs, with enrollment of more than 1,200 students. It has the largest graduate medical education program in the country, with more than 2,700 clinical residents and fellows training throughout the Health System. The Graduate School of Biomedical Sciences offers 12 degree-granting programs, conducts innovative basic and translational research, and trains more than 470 postdoctoral research fellows.

Ranked No. 9 nationwide in National Institutes of Health (NIH) grant funding, the Icahn School of Medicine at Mount Sinai is among the 90th percentile of U.S. private medical schools in Sponsored Programs Direct Expenditures per Principal Investigator, according to the Association of American Medical Colleges. More than 6,900 scientists, educators, and clinicians work within and across dozens of academic departments and multidisciplinary institutes with an emphasis on translational research and therapeutics. Through Mount Sinai Innovation Partners (MSIP), the Health System facilitates the real-world application and commercialization of medical breakthroughs made at Mount Sinai.

-------------------------------------------------------

* Mount Sinai Health System member hospitals: The Mount Sinai Hospital; Mount Sinai Brooklyn; Mount Sinai Morningside; Mount Sinai Queens; Mount Sinai South Nassau; Mount Sinai West; and New York Eye and Ear Infirmary of Mount Sinai.

Tags: Artificial Intelligence, Icahn School of Medicine at Mount Sinai, Ira Hofer, MD, Andrew B Leibowitz, MD, Girish N Nadkarni, MD, Mount Sinai Health System, Research

About the Mount Sinai Health System

Mount Sinai Health System is one of the nation’s leading integrated academic health systems and one of the largest in the New York metropolitan area. Its comprehensive system includes seven hospitals, more than 400 outpatient practices, over 600 research and clinical laboratories, the Icahn School of Medicine at Mount Sinai, the Graduate School of Biomedical Sciences, and the Mount Sinai Phillips School of Nursing. Together, the Health System comprises approximately 48,000 employees, more than 9,000 physicians, and 8,600 nurses.

As a leading learning health system, Mount Sinai combines clinical expertise with scientific discovery to improve patient care while training the next generation of health care and biomedical leaders. The Health System provides care across every stage of life, from prenatal care through geriatrics, while advancing personalized medicine through artificial intelligence, data science, and biomedical research.

Mount Sinai is consistently recognized among the nation’s leading academic health systems for patient care, research, and education. The Mount Sinai Hospital is ranked No. 1 in New York by Newsweek® and No. 7 in the U.S. on the magazine’s World’s Best Hospitals 2026 list. The Icahn School of Medicine at Mount Sinai ranks No. 9 among U.S. medical schools and No. 1 among freestanding medical schools for National Institutes of Health grant funding, reflecting the strength of its scientific enterprise and leadership in biomedical research.